Roche considers hostile bid for BioMarin Pharmaceuticals

The Swiss pharmaceuticals firm Roche is understood to be mulling a potential £8.7bn (US$14bn) hostile bid for BioMarin Pharmaceuticals. According to industry sources, there is speculation that Roche might table…